AI Article Synopsis

  • - Melasma is a challenging skin condition to treat, and this study investigates the use of human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) as a potential novel treatment option, focusing on their safety and efficacy.
  • - In the research, animal studies showed that hUCMSC-Exos could effectively penetrate deeper skin layers when combined with microneedles, laser treatments, and plasma therapy, while a clinical trial with 60 patients tested several treatment combinations.
  • - Results indicated that the combinations of hUCMSC-Exos treatments significantly improved treatment outcomes and patient satisfaction compared to a control group, while pain levels varied among the different treatment groups.

Article Abstract

Background And Objectives: Melasma is a refractory skin disease due to its complex pathogenesis and difficult treatment. Studies have found that human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) could serve as a novel cell-free therapeutic strategy in regenerative and esthetic medicine. It could potentially treat melasma, but the skin barrier is a challenge. In this study, we aim to explore the safety and efficacy of hUCMSC-Exos in the treatment of melasma and the means to promote its percutaneous penetration.

Materials And Methods: In the animal study about the effect of penetration, percutaneous penetration of PKH67-labeled hUCMSC-Exos was studied under microneedles, 1565 nm nonablative fractional laser (NAFL), and a plasma named Peninsula Blue Aurora Shumin Master (PBASM) treatments, observed by confocal laser scanning microscopy. In the clinical application study, 60 patients with melasma treated in our department were divided into four groups. NAFL combined with normal saline treatment was used for Group A. Microneedles, NAFL, and PBASM combined with hUCMSC-Exos treatments were used for Groups B, C, and D, respectively. Each patient received four treatments at 1-month intervals. Assessments were done using the degree of pain posttreatment, melasma area and severity score, improvement rate, physician global assessment score, satisfaction, and complications.

Results: In the animal study about the effect of penetration, hUCMSC-Exos can penetrate the deep dermis under microneedles, NAFL, and PBASM treatments. In the clinical application study, compared with Group A, Groups B, C, and D showed significantly improved therapeutic effect and patient satisfaction (p < 0.05), and there was no significant difference among Groups B, C, and D.(p > 0.05). Patients in Group B reported higher pain levels than those in the other three groups (p < 0.05); the treatment experience of patients in Group D was better.

Conclusion: hUCMSC-Exos can improve the symptoms of melasma safely and effectively. Compared with microneedles, NAFL and PBASM can also achieve a good effect toward promoting penetration. These findings are worthy of exploration and clinical application.

Download full-text PDF

Source
http://dx.doi.org/10.1002/lsm.23628DOI Listing

Publication Analysis

Top Keywords

stem cell-derived
8
cell-derived exosomes
8
treatment melasma
8
percutaneous penetration
8
animal study
8
study penetration
8
pbasm treatments
8
clinical application
8
application study
8
microneedles nafl
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!